XT
IMDX

XTX Topco’s Insight Molecular Diagnostics IMDX Stock Holding History

XTX Topco’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$63.4K Sell
10,743
-19,610
-65% -$96.8K ﹤0.01% 3655
2026
Q1 		$99.6K Buy
+30,353
New +$176K ﹤0.01% 3103

Other funds holding IMDX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
FOR
Family Office Research Bethesda, Maryland $267M AUM 27.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

XTX Topco's IMDX Position: Q2 2026 in Review

XTX Topco reduced its Insight Molecular Diagnostics (IMDX) stake by 65% in Q2 2026, selling an estimated $96.8K and leaving 10,743 shares worth $63.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3655.

XTX Topco first reported a position in IMDX in Q1 2026 and has held it in 2 quarters since. The position peaked at $99.6K in Q1 2026. 40 funds tracked by Wall St. Rank hold IMDX as of Q2 2026.

  • XTX Topco held 10,743 shares of Insight Molecular Diagnostics worth $63.4K as of Q2 2026.
  • XTX Topco sold 19,610 Insight Molecular Diagnostics shares in Q2 2026, an estimated $96.8K.
  • Insight Molecular Diagnostics made up ﹤0.01% of XTX Topco's portfolio in Q2 2026, its #3655 holding.
  • XTX Topco first reported a position in Insight Molecular Diagnostics in Q1 2026 and has held it in 2 quarters since.
  • XTX Topco's Insight Molecular Diagnostics position peaked at $99.6K in Q1 2026.
  • 40 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.